Serbian Biotech Startup Takes Its Journey from Belgrade to Cambridge with Documentary on Longevity Science
21.9.2026 13:02:00 CEST | Business Wire | Press release
BioEridan, a Serbian biotechnology company backed by Telekom Srbija Group’s TS Ventures Fund, has premiered a documentary charting its journey from an early scientific project in Belgrade to an emerging biotechnology venture focused on longevity research
BioEridan, a Serbian biotechnology startup backed by Telekom Srbija Group’s TS Ventures Fund, has premiered a new documentary showcasing its development of underwater Aquafarms and its ambition to contribute to the next generation of longevity science.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921345879/en/
BioEridan Documentary Premiere
BioEridan: Science Beneath the Surface premiered in Belgrade on September 15 before being screened the following day at a UK-Serbia Health, Digital Transformation & Innovation roundtable held at Christ’s College, University of Cambridge, as part of Cambridge Tech Week 2026.
The roundtable brought together prominent representatives from the UK and Serbia across science, healthcare, technology, academia and business to discuss opportunities for collaboration, innovation and the commercialisation of scientific research.
The documentary follows BioEridan’s development from an early scientific project in Serbia to the creation of underwater Aquafarms designed to support biotechnology research. Located approximately 13 metres beneath the sea, the Aquafarms use controlled hydroponic systems to cultivate plants in a highly controlled environment for biotechnology research.
At the heart of BioEridan’s mission is the pursuit of new approaches to longevity and healthy ageing, including research related to telomeres — protective structures at the ends of chromosomes that play an important role in cellular ageing. BioEridan is working on the production of a bioactive ingredient that it aims to develop for use in future longevity-focused products.
Dr Jelena Milovanović, Founder and CEO of BioEridan, said: “BioEridan was founded on the belief that transformative science can come from anywhere. This documentary tells the story of our journey and explores whether some of the next breakthroughs in longevity science may already exist in nature, waiting to be discovered. From Serbia, we want to build a new model for biotechnology that is ambitious in its science, responsible in its use of nature and capable of improving lives around the world.”
The screening at Christ’s College formed part of BioEridan’s participation in the UK-Serbia Health, Digital Transformation & Innovation Forum on September 16. The event provided an opportunity to present BioEridan’s research and technology to an international audience and to explore potential partnerships connecting Serbian scientific and entrepreneurial talent with the UK’s world-leading research and innovation ecosystem.
BioEridan is supported by TS Ventures Fund, the first corporate venture capital fund established in this part of Europe. Founded in 2021, the €25 million fund invests in technology and business solutions across Serbia and international markets, with areas of focus including life sciences, artificial intelligence, cybersecurity, fintech and software.
Davor Sakač, CEO of TS Ventures Fund, said: “BioEridan demonstrates the depth of scientific talent and entrepreneurial ambition emerging from Serbia. Its journey from Belgrade to Cambridge shows how a promising scientific idea can develop into a venture with international ambitions. The launch of this documentary and BioEridan’s participation in Cambridge Tech Week bring its story and technology to a wider global audience, while reflecting TS Ventures Fund’s role in helping promising companies develop, scale and build connections with leading innovation ecosystems.”
The documentary’s launch marks another milestone in BioEridan’s development as it expands its research capacity and international profile, with the ambition of establishing Serbia as a recognised contributor to biotechnology and longevity science.
About BioEridan
BioEridan is a Serbian biotechnology company focused on longevity research and the discovery and development of innovative bioactive compounds. The company combines biotechnology, marine science and controlled underwater cultivation through its proprietary Aquafarm platform, with the aim of developing new solutions for healthy ageing and supporting the next generation of longevity science.
About Telekom Srbija Group
Telekom Srbija Group is one of the leading telecommunications and technology companies in Southeast Europe, serving more than 14 million customers across 15 markets regionally and globally. The Group provides a comprehensive portfolio of connectivity, digital and multimedia services, while accelerating its transformation into the Telco of the Future through investments in next-generation infrastructure, 5G, artificial intelligence, cybersecurity, digital services and premium content. Through strategic partnerships and its innovation ecosystem, including TS Ventures Fund, Telekom Srbija Group is supporting the growth of new technologies and contributing to the digital transformation of the region and beyond.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260921345879/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom